These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34619465)

  • 1. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
    Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
    Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
    Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
    Lee HY; Fan SJ; Huang FI; Chao HY; Hsu KC; Lin TE; Yeh TK; Lai MJ; Li YH; Huang HL; Yang CR; Liou JP
    J Med Chem; 2018 Aug; 61(16):7087-7102. PubMed ID: 30028616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
    Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
    ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
    Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
    Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent innovative advances in the discovery of selective HDAC6 inhibitors.
    T Tavares M; Shen S
    Future Med Chem; 2021 Jun; 13(12):1017-1019. PubMed ID: 33906379
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
    Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
    ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
    Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
    Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
    Fan SJ; Huang FI; Liou JP; Yang CR
    Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
    He F; Chou CJ; Scheiner M; Poeta E; Yuan Chen N; Gunesch S; Hoffmann M; Sotriffer C; Monti B; Maurice T; Decker M
    J Med Chem; 2021 Apr; 64(7):3794-3812. PubMed ID: 33769811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTML Modeling for Alzheimer's Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6.
    Kleandrova VV; Speck-Planche A
    Curr Top Med Chem; 2020; 20(19):1661-1676. PubMed ID: 32515311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
    Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
    ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
    Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
    J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
    Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.